<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">
Skip to content
www.championsoncology.comhs-fshubfsChampions_Logo_New_White-2

Champions Oncology's Annual European Translational Oncology Symposium

Uncovering Integrative Approaches for IO & Oncology Drug Development 

Thursday, March 13th, 2025
8.30 AM - 4.00 PM
 

 

Together we can accelerate the development of new cancer therapies ultimately improving cancer patient outcomes and shape the future of oncology care. 

 

About Champions' Annual European Translational Oncology Symposium

 

We are excited to welcome you to our Annual European Translational Oncology Symposium on the March 13th, 2025 at the Hotel Victoria, Basel, Switzerland. Our exclusive symposium brings together leading researchers, clinicians, experts, and industry professionals to examine the latest advancements in cancer research and therapy. This symposium explores the crucial link between groundbreaking lab discoveries and their real-world clinical applications, focusing on innovations in personalized medicine, targeted therapies, immuno-oncology, and cancer research. Attendees will gain invaluable insights, collaborate, and engage with industry leaders from Roche, Ichonos Glenmark Innovation, Debiopharma, FoRx Therapeutics AG, and many more. Complimentary lunch will be served to all participants, and after the final session, please join us for drinks and hors d'oeuvres to continue the conversation. Your presence is crucial in advancing cancer care and fostering the progress of new treatments. We eagerly anticipate your attendance at this important gathering.

Meeting Objectives:

  • Advancement in Oncology: Learn from industry experts how to translate your scientific discoveries from the lab into new therapies, diagnostic research, and prevention strategies that directly benefit cancer patients.
  • Scientific Focus: The meeting is aimed at addressing challenges in the field of cancer therapy, development of novel therapeutics, and promoting significant advancements in cancer science through scientific collaborations.
  • Industry Engagement and Networking: The field is expanding with increasing involvement from major pharmaceutical companies and the meeting is aimed to foster formal and informal interactions among leading experts from biopharma companies.

This symposium is tailored towards:
R&D, discovery, preclinical, and translational teams from pharma and biotech should attend this ground-breaking event.